Resolution Therapeutics extends inflammatory and fibrotic pipeline (opens in new tab)

Resolution Therapeutics has expanded its inflammatory and fibrotic disease pipeline by executing material transfer agreements with independent lipid nanoparticle providers to evaluate LNP formulations for engineering the myeloid compartment in vivo. Under the agreements, Resolution will perform systematic, parallel assessments of lnp delivery vehicles while finalizing proprietary mRNA payloads, with preliminary results expected later this […] The post appeared first on <a href="